Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings

Reuters

23 May

Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings

Legend Biotech, a subsidiary of GenScript Biotech Corporation, is set to present new data on its CARVYKTI® therapy for patients with multiple myeloma at two major upcoming medical conferences. The data, part of the CARTITUDE Clinical Development Program, will be showcased at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association's (EHA) Congress. Legend Biotech, whose shares are listed on the Nasdaq Global Select Market, made this announcement following a Form 6-K filing with the United States Securities and Exchange Commission. For more detailed information, interested parties are encouraged to visit Legend Biotech's official website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2537973249"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537973249\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537973249?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 07:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537973249","market":"nz","top_or_hot":-1,"title":"Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Legend Biotech, a subsidiary of GenScript Biotech Corporation, is set to present new data on its CARVYKTI® therapy for patients with multiple myeloma at two major upcoming medical conferences. The data, part of the CARTITUDE Clinical Development Program, will be showcased at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association's (EHA) Congress. Legend Biotech, whose shares are listed on the Nasdaq Global Select Market, made this announcement following a Form 6-K filing with the United States Securities and Exchange Commission. For more detailed information, interested parties are encouraged to visit Legend Biotech's official website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-23 07:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Legend Biotech, a subsidiary of GenScript Biotech Corporation, is set to present new data on its CARVYKTI® therapy for patients with multiple myeloma at two major upcoming medical conferences. The data, part of the CARTITUDE Clinical Development Program, will be showcased at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association's (EHA) Congress. Legend Biotech, whose shares are listed on the Nasdaq Global Select Market, made this announcement following a Form 6-K filing with the United States Securities and Exchange Commission. For more detailed information, interested parties are encouraged to visit Legend Biotech's official website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL8rHtM7:1","article_id":"2537973249","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537973249","pubTimestamp":1747956543,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Legend Biotech, a subsidiary of GenScript Biotech Corporation, is set to present new data on its CARVYKTI therapy for patients with multiple myeloma at two major upcoming medical conferences. The data, part of the CARTITUDE Clinical Development Program, will be showcased at the 2025 American Society of Clinical Oncology  Annual Meeting and the European Hematology Association's  Congress. Legend Biotech, whose shares are listed on the Nasdaq Global Select Market, made this announcement following a Form 6-K filing with the United States Securities and Exchange Commission. For more detailed information, interested parties are encouraged to visit Legend Biotech's official website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Bi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"传奇生物将在2025年ASCO和EHA会议上公布治疗多发性骨髓瘤的新CARVYKTI数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":0.9,"LEGN":0.9},"content_text":"Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings\n    \n\n        Legend Biotech, a subsidiary of GenScript Biotech Corporation, is set to present new data on its CARVYKTI® therapy for patients with multiple myeloma at two major upcoming medical conferences. The data, part of the CARTITUDE Clinical Development Program, will be showcased at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association's (EHA) Congress. Legend Biotech, whose shares are listed on the Nasdaq Global Select Market, made this announcement following a Form 6-K filing with the United States Securities and Exchange Commission. For more detailed information, interested parties are encouraged to visit Legend Biotech's official website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}